Health
AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH
WILMINGTON, Del., December 04, 2025--AstraZeneca advances its ambition to redefine hematology care with new data from its diverse pipeline and portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6-9, 2025.
About this update from Astrazeneca Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1181,"height":286,"url":"https://media.zenfs.com/en/business-wire.com/9fe6411c17ccad0f3ec1bf4c75931240"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/A9zL.YTIlo3v8WiJde9b9Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIzMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/9fe6411c17ccad0f3ec1bf4c75931240","width":960,"height":232},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/LQGwTwgpw96e8Vh6h1Qopg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIzNjI7aD01NzI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/9fe6411c17ccad0f3ec1bf4c75931240","width":1181,"height":286}},"lazy":false},{"type":"text","content":"Investigational T-cell engager, surovatamig, and CAR T-cell therapy, AZD0120, will show potential with initial data across multiple blood cancers","length":145,"tagName":"p","attribs":{}},{"type":"text","content":"New results will showcase benefit of CALQUENCE® in patients with mantle cell lymphoma and chronic lymphocytic leukemia","length":118,"tagName":"p","attribs":{}},{"type":"text","content":"New data will further support clinical benefits of ULTOMIRIS® in paroxysmal nocturnal hemoglobinuria and its potential to improve outcomes for pediatric patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy","length":239,"tagName":"p","attribs":{}},{"type":"text","content":"WILMINGTON, Del., December 04, 2025--(BUSINESS WIRE)--AstraZeneca advances its ambition to redefine hematology care with new data from its diverse pipeline and portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6-9, 2025.","length":269,"tagName":"p"},{"type":"text","content":"This year’s ASH congress will feature the Company’s largest presence to date, with 65 abstracts across eight approved and investigational medicines, including 15 oral presentations.","length":181,"tagName":"p"},{"type":"text","content":"Key presentations include:","length":26,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Phase I trial of surovatamig: Updated results at three-year follow up from the ongoing first-in-human trial of surovatamig, a CD19xCD3 T-cell engager, in relapsed/refractory (R/R) follicular lymphoma (FL) (Oral Abstract #1005).","length":227,...